Meropenem Kabi (Meropenem Trihydrate)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, blocking the cross‑linking of peptidoglycan strands. This weakens the cell wall, causing osmotic rupture and bacterial death, providing broad‑spectrum activity against many Gram‑negative, Gram‑positive, and anaerobic organisms.

The dose of Meropenem Kabi is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. Dosage regimens are individualized and should follow the prescriber's instructions.

Safety data for Meropenem in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Meropenem Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Meropenem shares the broad‑spectrum, β‑lactam activity of other carbapenems such as imipenem and ertapenem, but it offers enhanced stability against many β‑lactamases and a slightly broader gram‑negative coverage. Choice among carbapenems depends on local resistance patterns, infection site, and patient‑specific factors.

Meropenem Kabi should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame recommended by the manufacturer and kept under the same temperature conditions.

Meropenem Kabi is administered by intravenous infusion, typically over 15‑30 minutes. The exact infusion rate and duration are set by the prescribing clinician, who will also determine the dosing schedule based on infection severity and patient renal function.

Serious risks include seizures (particularly in patients with renal impairment or pre‑existing CNS disorders), severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Prompt recognition and medical intervention are essential if any of these events occur.

Meropenem Kabi should be avoided in patients with a known hypersensitivity to carbapenems or other β‑lactam antibiotics. Caution is also advised for individuals with severe renal impairment, a history of seizures, or those receiving valproic acid, unless the prescriber determines the benefits outweigh the risks.